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Background
•Accurate, unbiased assessment of outcome events is critical to the interpretation of clinical trials.
•Central event adjudication by experts blinded to treatment assignment applying uniform criteria is the current standard for high-quality trials.
•The value of central events adjudication has recently been challenged. If disagreement in classification of event between local investigator and reviewer, entire subcommittee reviewed event, and final determination made by consensus
Adjudication Process
•There is suggestive evidence of biased reporting of ischemic stroke events by unblinded local investigators.
•While not statistically significantly different, clinically relevant differences in the effect of treatments on stroke were seen using unadjudicated vs. centrally adjudicated events.
•Stroke events rates were 26% lower using centrally adjudicated events.
•The likelihood of confirmation of locally reported events varied with the type of event.
•Given the large number of sites and different investigators in this unblinded trial, central event adjudication added importantly to understanding the relative effects of the interventions on cardiovascular outcomes and absolute event rates in AFFIRM.
Results -Stroke (first event per patient)

Results -Event Totals
•First reported event was defined as the earliest ischemic stroke for each patient, reported by local investigators •First adjudicated stroke was defined as earliest ischemic stroke for each patient as classified by adjudication process •Goal was to compare the stroke event that would have been counted in a time-to-failure analysis, with and without central adjudication
•Includes every event type reported by local investigators that went through adjudication process •This analysis compares the total number of reported and adjudicated events •It is possible that patients had more than one of each event type
The first reported stroke event was confirmed by the adjudication committee 77% (147/189) of the time overall, 83% (73/88) of the time for rate control and 73% (74/101) of the time for rhythm control (p=0.11) Using reported events, the risk of stroke was 15% higher using rhythm compared to rate. Based on adjudicated events, the risk was 4% higher (p=ns in both cases). While the primary outcome was mortality, a key secondary endpoint was ischemic stroke (IS), centrally adjudicated by those reviewing source documents from which data regarding rate/rhythm treatment was purged. Results: 190 cases of first IS were submitted by local investigators, and 141 (74%) were confirmed after adjudication. More submitted IS were excluded in the rhythm control arm. The first reported stroke event was confirmed by the adjudication committee 83% (73/88) of the time for rate control and 73% (74/101) of the time for rhythm control (p=0.11). Based on IS confirmed by adjudication, there was no evidence of a treatment difference (HR=1.04, p=0.79). While examining first IS regardless of adjudication also did not provide evidence of a treatment difference, the hazard ratio was appreciably increased (HR=1.15) and the p-value decreased (p=0.33). The instantaneous risk of stroke was 4% higher with rhythm compared to rate based on adjudicated events, and 15% higher using reported events. Conclusions: 1. There is evidence for biased reporting of IS by unblinded local investigators. 2. Using first adjudicated IS or first reported IS results in different estimates of event rates and treatment effects that are clinically relevant. 3. Central blinded event adjudication importantly altered the key IS outcome in the AFFIRM trial.
Adjudicated Stroke, continued
•The rate of confirmation of cardiovascular events by central adjudication varied significantly according to the type of event, from a high of 98% for myocardial infarctions to a low of 36% for non-CNS emboli.
•Based on first reported ischemic stroke, 15/24 (63%) patients in Canada had event confirmed versus 132/165 (80%) in the US (p=0.054) 
